Log in  First Connection?

VaccinesArchives

Brucellosis novel multi-epitope vaccine design based on in silico analysis focusing on Brucella abortus
Vaccines
 9 min.

 Published on 10/07/2025 |  Original article (Full-text)  | Gharazi Houraalsadat et al. | BMC Immunology 2025; 26(1): 46

Brucella is a minute, spherical, gram-negative bacterium that lacks buds, flagella, and pods. Brucella is classified into several different categories (B. melitensis, B. abortus, B. suis) and has been well-documented in earlier research [1]. Brucella...

Advertisement
Advertisement

Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers
Vaccines
 1 min.

 Published on 03/07/2025 |  Original article (Full-text)  | Dipesh Tamrakar et al. | Human vaccines & immunotherapeutics 2024; 20(1):

Typhoid fever is a significant public health concern with most of the sufferers between 15 and 25 y of age in Nepal. We undertook this study to demonstrate Vi polysaccharide conjugated with diphtheria toxoid (Vi-DT) conjugate vaccine which is non-inferior to Typbar typhoid conjugate vaccine, a...

Plasmodium falciparum merozoite surface protein 1 as asexual blood stage malaria vaccine candidate
Vaccines
 1 min.

 Published on 26/06/2025 |  Original article (Full-text)  | Richard Thomson-Luque et al. | Expert Review of Vaccines 2024; 23(1): 160-73

Malaria represents a public health challenge in tropical and subtropical regions, and currently deployed control strategies are likely insufficient to drive elimination of malaria. Development and improvement of malaria vaccines might be key to reduce disease burden. Vaccines targeting asexual blood...

Assessing linearity of vaccine immunogenicity assays: application and link with clinical endpoints
Vaccines
 1 min.

 Published on 19/06/2025 |  Original article (Full-text)  | Capucine Lepers et al. | Bioanalysis 2025; 17(9): 583-94

Assessing the performance of an immunogenicity assay before using it to support vaccine clinical trials is mandatory. Further validation of assay performance is even requested to support Phase III studies. While assay validation requires adherence to predefined acceptance criteria, there is no universal...

The indirect effect of the bivalent human papillomavirus vaccination program: an observational cohort study
Vaccines
 5 min.

 Published on 12/06/2025 |  Original article (Full-text)  | Middeldorp Marit et al. | BMC Medicine 2025; 23(1): 335

A persistent infection with a high-risk type of human papillomavirus (HPV) is the established cause of cervical cancer [1]. Since 2006, prophylactic vaccination is available to prevent HPV-associated diseases. High vaccine efficacy and vaccine effectiveness against persisting vaccine-type infections...